References
- Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011;29:487–494.
- Burnett A, Milligan D, Prentice A, . A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007;109:1114–1124.
- Macdonald D, Assouline S, Brandwein J, . A phase I/II study of soragenib (Bay 43-9006) in combination with low dose cytarabine (LDAC) in elderly patients with AML or high-risk MDS from the NCIC clinical trials group: Trial Ind. 186. Leukemia and Lymphoma 2013;54:760–766.
- Juliusson G, Antunovic P, Derolf Å, . Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009;113:4179–4187.
- Kantarjian H, O'Brien S, Cortes J, . Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106:1090–1098.
- Fenaux P, Mufti GJ, Hellstrom-Lindberg E, . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223–232.
- Inaba H, Rubnitz JE, Coustan-Smith E, . Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol 2011;29:3293–3300.
- Borthakur G, Kantarjian H, Ravandi F, . Phase 1 study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 2010;96:62–68.
- Ravandi F, Cortes J, Jones D, . Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010;28:1856–1862.
- Schneider F, Hoster E, Schneider S, . Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Ann Hematol 2012;91:9–18.
- Dicker F, Haferlach C, Sundermann J, . Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia 2010;24:1528–1532.
- Bacher U, Haferlach T, Kern W, . A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 2007;92:744–752.
- Whitman SP, Maharry K, Radmacher MD, . FLT3 internal tandem duplication associates with adverse outcome and gene-and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010;116:3622–3626.
- Man CH, Fung TK, Ho C, . Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent non-responsiveness associated with a D835 mutation. Blood 2012;119:5133–5143.
- Smith CC, Wang Q, Chin CS, . Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012;485:260–263.
- Sato T, Yang X, Knapper S, . FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 2011;117:3286–3293.